Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria
- PMID: 6225118
- PMCID: PMC384270
- DOI: 10.1073/pnas.80.17.5430
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria
Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia in which the erythrocytes are abnormally sensitive to lysis by complement. A functional deficiency of membrane-associated complement regulators has been demonstrated on PNH erythrocytes. The two factor H-like proteins, the C3b receptor (CR1) and the decay-accelerating factor (DAF), were isolated from normal human erythrocytes, and specific antisera were prepared. Selective inhibition of the two proteins on normal erythrocytes by the antisera demonstrated (i) that the factor responsible for accelerated decay of erythrocyte-bound C3 convertase is DAF and (ii) that the cofactor required for inactivation of erythrocyte-bound C3b by factor I is CR1. PNH erythrocytes were deficient in both of these activities. Erythrocytes deficient in CR1, which were obtained from an apparently healthy individual, exhibited normal DAF activity but no factor I cofactor activity. These cells were not susceptible to complement-mediated lysis in acidified human serum, whereas PNH erythrocytes and Pronase-treated human erythrocytes (which lack DAF and CR1 activities) were lysed by this treatment. It is suggested that the protein primarily responsible for preventing complement activation on normal human erythrocytes is DAF. AMr 73,000 protein isolated from the normal erythrocyte membranes of one PNH patient by using anti-DAF IgG was largely absent from the abnormal erythrocytes of this individual, suggesting that PNH cells lack the DAF protein. CR1 antigen, however, was present on the abnormal PNH erythrocytes. The results suggest that the primary molecular defect underlying the clinical manifestations of PNH may be the lack of the membrane-associated DAF protein and that the abnormal cells may also exhibit impaired CR1 function.
Similar articles
-
Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.Proc Natl Acad Sci U S A. 1983 Aug;80(16):5066-70. doi: 10.1073/pnas.80.16.5066. Proc Natl Acad Sci U S A. 1983. PMID: 6576376 Free PMC article.
-
Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria.J Immunol. 1985 Jan;134(1):512-7. J Immunol. 1985. PMID: 2578050
-
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.J Exp Med. 1983 Jun 1;157(6):1971-80. doi: 10.1084/jem.157.6.1971. J Exp Med. 1983. PMID: 6222136 Free PMC article.
-
Erythrocyte membrane protein deficiencies in paroxysmal nocturnal hemoglobinuria.Am J Med. 1989 Sep;87(3N):22N-29N. Am J Med. 1989. PMID: 2484793 Review.
-
Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.J Exp Med. 1985 Jul 1;162(1):75-92. doi: 10.1084/jem.162.1.75. J Exp Med. 1985. PMID: 2409211 Free PMC article. Review.
Cited by
-
Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization.Virology. 2016 Oct;497:305-313. doi: 10.1016/j.virol.2016.07.030. Epub 2016 Aug 6. Virology. 2016. PMID: 27505156 Free PMC article.
-
Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor.J Exp Med. 1987 Oct 1;166(4):1011-25. doi: 10.1084/jem.166.4.1011. J Exp Med. 1987. PMID: 3309123 Free PMC article.
-
Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.Clin Exp Immunol. 1992 Mar;87(3):415-21. doi: 10.1111/j.1365-2249.1992.tb03012.x. Clin Exp Immunol. 1992. PMID: 1371955 Free PMC article.
-
Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.J Exp Med. 1986 May 1;163(5):1150-61. doi: 10.1084/jem.163.5.1150. J Exp Med. 1986. PMID: 2422313 Free PMC article.
-
Decay-accelerating factor. Genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans.J Exp Med. 1987 Jul 1;166(1):246-52. doi: 10.1084/jem.166.1.246. J Exp Med. 1987. PMID: 2439634 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous